Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:37:20.123Z.
Consensus retrieved: 2026-10-06T14:00:11.934Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:37:20.123Z.
Quote observation: 2026-10-06T17:35:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69a1d57d3f318828ebe19021960b74268097702d5d6050a421f3255bba496414
Forward PE Ratio (N/A) = Dated Quote Price ($11.04) / Consensus Forward EPS ($-3.37)
FORWARD PE RATIO
N/A
MoonLake Immunotherapeutics
Market Cap
$928.21M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $928.21M | N/A |
| CeriBell, Inc. (CBLL)vs › | $932.78M | N/A |
| HealthStream, Inc. (HSTM)vs › | $916.33M | 42.50 |
| Kura Oncology, Inc. (KURA)vs › | $942.07M | N/A |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $946.76M | N/A |
| Savara Inc. (SVRA)vs › | $949.84M | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $901.07M | N/A |
| Bioventus Inc. (BVS)vs › | $896.31M | 16.99 |
| Aktis Oncology, Inc. (AKTS)vs › | $965.56M | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.38M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $11.04, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.37 | $-3.58 – $-3.17 | 6 | n/m |
| 2027-12-31 | $-3.41 | $-4.20 – $-2.67 | 8 | n/m |
| 2028-12-31 | $-2.66 | $-4.09 – $-0.88 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
